Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Disorders of the Nervous Tissue

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Rational Basis for Personalized Treatment Using Concentration-Guided Dosing.

Therapeutic drug monitoring·2025

Same author

Imputation of missing clock times - application to procalcitonin concentration time course after birth.

Journal of pharmacokinetics and pharmacodynamics·2025

Same author

A pharmacokinetic framework describing antibiotic adsorption to cardiopulmonary bypass devices.

CPT: pharmacometrics & systems pharmacology·2024

Same author

Covariate modeling in pharmacometrics: General points for consideration.

CPT: pharmacometrics & systems pharmacology·2024

Same author

A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization.

Clinical pharmacology and therapeutics·2024

Same author

A physiological approach to renal clearance: From premature neonates to adults.

British journal of clinical pharmacology·2023

Search research articles

Related Experiment Video

Updated: May 12, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Disease progression and neuroscience.

Nick Holford¹

¹Department of Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand. n.holford@auckland.ac.nz

Journal of Pharmacokinetics and Pharmacodynamics

|April 18, 2013

Summary

Understanding disease progression and placebo response is crucial for identifying true drug effects in neurological disorders. This study proposes criteria to differentiate symptomatic from disease-modifying treatments.

Area of Science:

Neurology
Clinical Pharmacology
Biostatistics

Background:

Disease progression varies significantly across neurological disorders.
Placebo responses can confound the assessment of treatment efficacy.
Distinguishing drug effects from natural disease course and placebo is a critical challenge in clinical trials.

Purpose of the Study:

To discuss the concepts of disease progression in neurological disorders.
To highlight the importance of analyzing placebo response over time.
To propose criteria for differentiating symptomatic and disease-modifying drug effects.

Main Methods:

Conceptual analysis of disease progression and placebo response.
Development of criteria for evaluating drug effects.

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Related Experiment Videos

Last Updated: May 12, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Application of criteria to interpret clinical trial data.

Main Results:

Disease progression and placebo response must be accounted for to reliably identify drug effects.
Proposed criteria aid in distinguishing between symptomatic and disease-modifying treatments.
Interpretation of clinical trial results in various neurological conditions.

Conclusions:

Reliable identification of therapeutic drug effects necessitates careful consideration of disease progression and placebo response.
The proposed criteria offer a framework for evaluating drug efficacy in neurological trials.
This approach is applicable across diverse conditions including Alzheimer's disease and Parkinson's disease.